Fibrates, specific pharmacological agonists of PPARα, have been widely used to treat hypercholesterolemia and hypertriglyceridemia. Apart from their metabolic action, anti-inflammatory properties of fibrates have been described, including inhibition of NF-kappa B signaling and pro-inflammatory cytokine production. 4 Fenofibrate, an important peroxisome proliferator-activated receptor-a (PPAR- α) agonist, is widely used in clinical as a triglyceride (TG)-lowering agent
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
60
mesalamine is the cornerstone used for the treatment of mild to moderate ulcerative colitis
Fibrates, which are specific pharmacological agonists of PPARα, have been widely used in the treatment for hypercholesterolemia and hypertriglyceridemia
Faculty of Medicine, Menoufia University
Tanta, Shebeen El-Kom, Egypt
• The primary endpoint is the change in disease activity index and the improvement in health-related quality of life (HRQL).
• The primary endpoint is the change in disease activity index and the improvement in health-related quality of life (HRQL).
Time frame: 6 months
The secondary endpoint is estimated by changes in serum biomarkers.
The secondary endpoint is estimated by changes in serum biomarkers such as adenosine monophosphate activated protein kinase
Time frame: 6 months
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.